Paper3708002
Iron mobilisation from lactoferrin by chelators at physiological pH.
Kontoghiorghes GJ. Biochim Biophys Acta, 1986. Cited by 34 papers, by iCite.
Cite this record
ConductScience Library. Iron mobilisation from lactoferrin by chelators at physiological pH. Papers, record 3708002. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3708002
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Iron | Major topic |
| Lactoferrin | Major topic |
| Lactoglobulins | Major topic |
| Chelating Agents | |
| Female | |
| Humans | |
| Hydrogen-Ion Concentration | |
| Milk, Human |
Source PubMed
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41596074 | Targeting Aging and Diseases Associated with Ferroptosis and Senescence Through Modulation of Iron, Oxidative Stress and Lipid Peroxidation. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/41596074 | PubMed |
| 41156522 | Development of Iron-Chelating/Antioxidant Nutraceuticals and Natural Products as Pharmaceuticals for Clinical Use in Diseases with Free Radical Pathologies. | Nutrients | 2025 | https://conductscience.org/library/papers/41156522 | PubMed |
| 39857363 | New Insights into Aspirin's Anticancer Activity: The Predominant Role of Its Iron-Chelating Antioxidant Metabolites. | Antioxidants (Basel) | 2024 | https://conductscience.org/library/papers/39857363 | PubMed |
| 38892142 | Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38892142 | PubMed |
| 37513928 | The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37513928 | PubMed |
| 36430469 | New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36430469 | PubMed |
| 35163169 | Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163169 | PubMed |
| 34074010 | New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34074010 | PubMed |
| 32751493 | Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications. | Medicines (Basel) | 2020 | https://conductscience.org/library/papers/32751493 | PubMed |
| 32545424 | Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases. | Cells | 2020 | https://conductscience.org/library/papers/32545424 | PubMed |
| 27822363 | Structure and domain dynamics of human lactoferrin in solution and the influence of Fe(III)-ion ligand binding. | BMC Biophys | 2016 | https://conductscience.org/library/papers/27822363 | PubMed |
| 27019793 | New developments and controversies in iron metabolism and iron chelation therapy. | World J Methodol | 2016 | https://conductscience.org/library/papers/27019793 | PubMed |
| 26610453 | Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology. | Molecules | 2015 | https://conductscience.org/library/papers/26610453 | PubMed |
| 12825969 | Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. | Drug Saf | 2003 | https://conductscience.org/library/papers/12825969 | PubMed |
| 8262586 | Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. | Indian J Pediatr | 1993 | https://conductscience.org/library/papers/8262586 | PubMed |
| 3122880 | Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. | Br Med J (Clin Res Ed) | 1987 | https://conductscience.org/library/papers/3122880 | PubMed |
| 2805610 | Iron-binding proteins and free iron in synovial fluids of rheumatoid arthritis patients. | Clin Rheumatol | 1989 | https://conductscience.org/library/papers/2805610 | PubMed |
| 1723362 | Drug antioxidant effects. A basis for drug selection? | Drugs | 1991 | https://conductscience.org/library/papers/1723362 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3708002
GET https://conductscience.org/api/papers/v1/3708002/authors